Correction of iron deficiency in hospitalized heart failure patients does not improve patient outcomes
| Autor: | Andrew Kohut, Patricia Locantore-Ford, Ronak Mistry |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Anemia medicine.medical_treatment Iron Immunology Population Intravenous iron Iron supplement Biochemistry Patient Readmission 03 medical and health sciences 0302 clinical medicine Quality of life Internal medicine medicine Humans Mortality education Aged Retrospective Studies Heart Failure education.field_of_study Hematology biology Anemia Iron-Deficiency Surrogate endpoint business.industry Cell Biology Iron Deficiencies General Medicine Iron deficiency Inpatient setting Middle Aged Prognosis medicine.disease Ferritin Hospitalization Treatment Outcome 030220 oncology & carcinogenesis Heart failure biology.protein Administration Intravenous Female business 030215 immunology |
| Zdroj: | Annals of Hematology. 100:661-666 |
| ISSN: | 1432-0584 0939-5555 |
| Popis: | Background: Heart failure (HF) is a chronic medical condition that affects approximately 1-2% of the world's population and greater than 10% of those age 65 and older. Among patients with HF, iron deficiency (ID), defined as ferritin Methods: We performed a retrospective analysis of hospital records of patients admitted with HF as a primary or secondary diagnosis to a city-based large academic teaching health system between April 1, 2014 and April 1, 2017. Thereafter, we identified those patients who had sufficient iron studies (hemoglobin, iron, ferritin, transferrin, TSat) during their hospitalization to diagnose ID, as per the criteria above. Patients with ID were then stratified into those that did and did not receive IVFe. Patient charts were evaluated to two primary endpoints, namely one-year readmissions for HF and patient mortality. Results: In total, 390 patients had sufficient iron studies performed to assess ID status, of which 279 met criteria for ID (71.5%). Eighty-four of the 279 patients received IVFe. Amongst patients that received IVFe, 38 patients were readmitted for HF (45.2%) and 6 patient deaths occurred within 1 year (7.14%). Amongst the remaining 195 patients who did not receive IVFe, 93 were readmitted for HF (47.69%) and 15 patient deaths occurred within 1 year (7.69%). Conclusion: These data suggest that despite clinical benefit in patient functional outcomes and overall quality of life in chronic heart failure patients treated with IVFe, treatment of ID in acute HF patients does not result in a reduction in admissions for HF or improvements in patient mortality. Disclosures No relevant conflicts of interest to declare. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink